Vect Revenue and Competitors

MARSEILLE ,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Vect's estimated annual revenue is currently $7.4M per year.(i)
  • Vect's estimated revenue per employee is $155,000

Employee Data

  • Vect has 48 Employees.(i)
  • Vect grew their employee count by 9% last year.

Vect's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$18.9M90-5%N/AN/A
#2
$52.9M1789%N/AN/A
#3
$84.2M4570%$2.6MN/A
#4
$14.9M103-49%N/AN/A
#5
$3.5M24-48%N/AN/A
Add Company

What Is Vect?

VECT-HORUS, Breaking barriers Vect-Horus designs and develops vectors that facilitate targeting and delivery of therapeutic or imaging agents to organs, including the brain and tumours. Vect-Horus combines these different agents to its vectors that specifically target various receptors, allowing these agents to cross natural barriers (first and foremost the blood-brain-barrier) which limit access of therapeutic or imaging agents to their targets. The proof of concept of the technology has already been established in animal models using different vectorized molecules. Vect-Horus endorces a mixed business model, based on its proprietary VECTrans® technology, both to make its technology platform available to pharmaceutical and biotechnology company partners and to develop an internal pipeline of products. Created in 2005, Vect-Horus is a spin-off of the Institute for Neurophysiopathology (INP, UMR7051, CNRS and Aix Marseille University), headed by Dr Michel Khrestchatisky, co-founder. Based in Marseille, France, the company has 35 employees, mostly in R&D, and develops academic collaborations with the CNRS, INSERM and CEA as well as industrial partnerships.

keywords:N/A

N/A

Total Funding

48

Number of Employees

$7.4M

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Vect News

2022-04-17 - 2022-04-21 | NDAQ:VECT | Press Release | VectivBio Holding ...

VectivBio Appoints Patrick Malloy as Senior Vice President, Investor Relations & Strategic Communications. VECT | 12 hours ago. Arena Pharmaceuticals and...

2022-04-17 - VectivBio (NASDAQ:VECT) Raised to “Hold” at Zacks ...

VectivBio (NASDAQ:VECT) Raised to “Hold” at Zacks Investment Research. Posted by admin on Apr 20th, 2022. Share on Twitter Share on Facebook Share on...

2022-04-06 - VectivBio Holding AG (VECT) CEO Luca Santarelli on Q4 2021 Results - Earnings Call Transcript

VectivBio Holding AG (NASDAQ:VECT) Q4 2021 Earnings Conference Call April 7, 2022 8:00 AM ET. Company Participants.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.4M4837%N/A
#2
$5.4M484%N/A
#3
$7.6M49N/AN/A
#4
$10.2M500%N/A
#5
N/A5028%N/A